Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, S.
Right arrow Articles by Berenson, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, S.
Right arrow Articles by Berenson, G. S.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 52:1265-1269, 2003
© 2003 by the American Diabetes Association, Inc.

The Peroxisome Proliferator-Activated Receptor-{gamma}2 Gene Polymorphism (Pro12Ala) Beneficially Influences Insulin Resistance and Its Tracking From Childhood to Adulthood

The Bogalusa Heart Study

Shengxu Li1, Wei Chen1, Sathanur R. Srinivasan1, Eric Boerwinkle2, and Gerald S. Berenson1

1 Tulane Center for Cardiovascular Health and Department of Epidemiology, Tulane University Health Sciences Center, New Orleans, Louisiana
2 Human Genetics Center and Institute of Molecular Medicine, University of Texas-Houston Health Science Center, Houston, Texas

The peroxisome proliferator-activated receptor (PPAR)-{gamma}2 gene polymorphism Pro12Ala has been associated with increased insulin sensitivity in some but not all studies. Little is known about its effect on the tracking of insulin resistance status over time. These aspects were examined in a community-based sample of 686 white young adults, aged 20–38 years, and 426 white children, aged 4–17 years, and a subsample of a cohort (n = 362) who participated both as children and adults, with an average follow-up period of 13.4 years. Insulin resistance was measured by the homeostasis model assessment of insulin resistance (HOMA-IR) using fasting insulin and glucose. The frequency of the variant Ala12 allele was 0.104 in whites vs. 0.017 in blacks. After adjusting for sex, age, and BMI, adult subjects with the genotype Pro/Pro, Pro/Ala, and Ala/Ala, respectively, showed significant decreasing trends in fasting insulin (11.7, 10.3, and 8.8 µU/ml; P = 0.002) and HOMA-IR (2.4, 2.1, and 1.7; P = 0.006). Similar but nonsignificant trends were noted in childhood. A significant genotype-BMI interaction effect on insulin (P = 0.020), glucose (P = 0.007), and HOMA-IR (P = 0.001) was found in adulthood, with carriers versus noncarriers showing attenuated association with BMI. The genotype-BMI interaction effect on these variables tended to be similar in childhood. With respect to tracking over time, of individuals in the top age- and sex-specific quartile of HOMA-IR in childhood, 48.7% (38/78) of noncarriers vs. 16.7% (2/12) of the carriers (P = 0.035) remained in the same quartile in adulthood. A similar trend was observed for insulin (2/13 vs. 35/77, P = 0.037). In conclusion, the Pro12Ala polymorphism of the PPAR-{gamma}2 gene beneficially influences insulin resistance and its tracking from childhood to adulthood. Further, the Ala12 allele attenuates the adverse association between adiposity and insulin resistance measures.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
A. Tonjes, M. Scholz, M. Loeffler, and M. Stumvoll
Association of Pro12Ala Polymorphism in Peroxisome Proliferator-Activated Receptor {gamma} With Pre-Diabetic Phenotypes: Meta-analysis of 57 studies on nondiabetic individuals.
Diabetes Care, November 1, 2006; 29(11): 2489 - 2497.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
S Sookoian, S I Garcia, P I Porto, G Dieuzeide, C D Gonzalez, and C J Pirola
Peroxisome proliferator-activated receptor gamma and its coactivator-1 alpha may be associated with features of the metabolic syndrome in adolescents
J. Mol. Endocrinol., October 1, 2005; 35(2): 373 - 380.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
D. M. Mutch, W. Wahli, and G. Williamson
Nutrigenomics and nutrigenetics: the emerging faces of nutrition
FASEB J, October 1, 2005; 19(12): 1602 - 1616.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Stefan, S. Schafer, F. Machicao, J. Machann, F. Schick, C. D. Claussen, M. Stumvoll, H.-U. Haring, and A. Fritsche
Liver Fat and Insulin Resistance Are Independently Associated with the -514C>T Polymorphism of the Hepatic Lipase Gene
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4238 - 4243.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. Knouff and J. Auwerx
Peroxisome Proliferator-Activated Receptor-{gamma} Calls for Activation in Moderation: Lessons from Genetics and Pharmacology
Endocr. Rev., December 1, 2004; 25(6): 899 - 918.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
K. L. Gatford, M. J. De Blasio, P. Thavaneswaran, J. S. Robinson, I. C. McMillen, and J. A. Owens
Postnatal ontogeny of glucose homeostasis and insulin action in sheep
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E1050 - E1059.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2003 by the American Diabetes Association.